These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20708903)

  • 1. Effect of contrast-induced nephropathy on cardiac outcomes after use of nonionic isosmolar contrast media during coronary procedure.
    Cho JY; Jeong MH; Hwan Park S; Kim IS; Park KH; Sim DS; Yoon NS; Yoon HJ; Park HW; Hong YJ; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    J Cardiol; 2010 Nov; 56(3):300-6. PubMed ID: 20708903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment.
    Pyxaras SA; Sinagra G; Mangiacapra F; Perkan A; Di Serafino L; Vitrella G; Rakar S; De Vroey F; Santangelo S; Salvi A; Toth G; Bartunek J; De Bruyne B; Wijns W; Barbato E
    Am J Cardiol; 2013 Mar; 111(5):684-8. PubMed ID: 23261003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preprocedural score for risk of contrast-induced nephropathy in elective coronary angiography and intervention.
    Maioli M; Toso A; Gallopin M; Leoncini M; Tedeschi D; Micheletti C; Bellandi F
    J Cardiovasc Med (Hagerstown); 2010 Jun; 11(6):444-9. PubMed ID: 20164783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
    Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Nephropathy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.
    Kocas C; Yildiz A; Abaci O; Karaca OS; Firdin N; Dalgic Y; Bostan C; Ersanli M
    Angiology; 2015 Nov; 66(10):964-8. PubMed ID: 25852211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial.
    Vasheghani-Farahani A; Sadigh G; Kassaian SE; Khatami SM; Fotouhi A; Razavi SA; Mansournia MA; Yamini-Sharif A; Amirzadegan A; Salarifar M; Sadeghian S; Davoodi G; Borumand MA; Esfehani FA; Darabian S
    Am J Kidney Dis; 2009 Oct; 54(4):610-8. PubMed ID: 19619921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Effects and Clinical Investigations for Contrast-Induced Nephropathy After Coronary Angiography or Percutaneous Coronary Intervention in Patients With Diabetes.
    Zhang MM; Lv QZ; Li XY
    Am J Ther; 2017; 24(4):e423-e430. PubMed ID: 26308327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and risk factors of contrast-induced nephropathy after cardiac catheterization in type II diabetic patients: a study among Egyptian patients.
    Sany D; Refaat H; Elshahawy Y; Mohab A; Ezzat H
    Ren Fail; 2014 Mar; 36(2):191-7. PubMed ID: 24138570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.
    Kim SJ; Choi D; Ko YG; Kim JS; Han SH; Kim BK; Kang SW; Hong MK; Jang Y; Choi KH; Yoo TH
    Am J Cardiol; 2011 Oct; 108(8):1086-91. PubMed ID: 21791335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of contrast-induced nephropathy in patients with chronic renal insufficiency undergoing multidetector computed tomographic angiography treated with preventive measures.
    El-Hajjar M; Bashir I; Khan M; Min J; Torosoff M; DeLago A
    Am J Cardiol; 2008 Aug; 102(3):353-6. PubMed ID: 18638601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
    Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
    Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical impact of nephropathy induced by contrast medium in patients with acute myocardial infarction undergoing emergent coronary angiography].
    Jujo K; Yamaguchi J; Obayashi K; Suzuki K; Sekiguchi H; Nagashima M; Tsurumi Y; Kasanuki H
    J Cardiol; 2006 Jul; 48(1):9-16. PubMed ID: 16886495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
    Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
    Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-induced nephropathy and risk of acute kidney injury and mortality after cardiac operations.
    Garcia S; Ko B; Adabag S
    Ann Thorac Surg; 2012 Sep; 94(3):772-6. PubMed ID: 22835553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-induced nephropathy in urgent coronary interventions.
    Valente S; Lazzeri C; Giglioli C; Margheri M; Comeglio M; Nicolaci L; Chechi T; Gensini GF
    J Cardiovasc Med (Hagerstown); 2006 Oct; 7(10):737-41. PubMed ID: 17001234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention.
    Barbieri L; Verdoia M; Suryapranata H; De Luca G;
    Int J Cardiol; 2019 Jan; 275():48-52. PubMed ID: 30274753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.